Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

BLRX

Bioline Rx Ltd ADR

Apr 18 • 04:00PM ET

0.6401

Dollar change +0.0187
Percentage change 3.01	%

Healthcare • Biotechnology • Israel • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	0.56%	Shs Outstand	79.94M	Perf Week	-8.56%
Market Cap	51.17M	Forward P/E	-	EPS next Y	-0.93	Insider Trans	0.00%	Shs Float	79.50M	Perf Month	-45.75%
Income	-60.61M	PEG	-	EPS next Q	-0.29	Inst Own	1.40%	Short Float	0.74%	Perf Quarter	-52.59%
Sales	4.80M	P/S	10.66	EPS this Y	-15.02%	Inst Trans	132.20%	Short Ratio	1.39	Perf Half Y	-56.46%
Book/sh	0.18	P/B	3.51	EPS next Y	9.71%	ROA	-86.40%	Short Interest	0.59M	Perf Year	-40.18%
Cash/sh	0.54	P/C	1.19	EPS next 5Y	-	ROE	-189.23%	52W Range	0.61 - 2.53	Perf YTD	-59.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.53%	ROI	-286.71%	52W High	-74.70%	Beta	1.51
Dividend TTM	-	Quick Ratio	1.47	Sales past 5Y	0.00%	Gross Margin	8.96%	52W Low	4.93%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	1.53	EPS Y/Y TTM	-93.34%	Oper. Margin	-895.65%	RSI (14)	28.55	Volatility	8.77% 10.29%
Employees	38	Debt/Eq	0.88	Sales Y/Y TTM	-	Profit Margin	-1262.79%	Recom	1.00	Target Price	13.75
Option/Short	Yes / Yes	LT Debt/Eq	0.60	EPS Q/Q	-105.91%	Payout	-	Rel Volume	0.72	Prev Close	0.62
Sales Surprise	3100.00%	EPS Surprise	13.64%	Sales Q/Q	-	Earnings	Mar 26 BMO	Avg Volume	426.10K	Price	0.64
SMA20	-28.89%	SMA50	-40.52%	SMA200	-55.76%	Trades		Volume	305,750	Change	3.01%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-17	Upgrade	Maxim Group	Hold → Buy	$1 → $3
Feb-13-17	Initiated	Rodman & Renshaw	Buy	$3
Aug-12-16	Downgrade	Maxim Group	Buy → Hold	$4 → $1
Aug-17-15	Reiterated	Maxim Group	Buy	$8 → $4
Jul-27-15	Reiterated	ROTH Capital	Buy	$10.50 → $7
Jun-22-15	Initiated	JMP Securities	Mkt Outperform	$5

Apr-17-24 07:00AM	BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting (PR Newswire)
Apr-10-24 07:00AM	BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement (PR Newswire)
Apr-01-24 09:00AM	BioLineRx Announces $6 Million Registered Direct Offering (PR Newswire) -23.20%
Mar-27-24 12:23PM	BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript (Insider Monkey) +7.77%
Mar-26-24 07:00AM	BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire) -20.77%
07:00AM	Loading…
Mar-20-24 07:00AM	BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 (PR Newswire)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-04-24 07:00AM	BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production (PR Newswire)
Feb-28-24 07:00AM	BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) (PR Newswire) +7.32%
Feb-25-24 02:12PM	3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond (InvestorPlace)
Feb-16-24 07:00AM	BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® (PR Newswire) +13.12%
Dec-21-23 07:00AM	BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease (PR Newswire) +5.06%
Nov-21-23 03:45PM	BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript (Insider Monkey) -10.59%
Nov-20-23 07:00AM	BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Nov-13-23 07:00AM	BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 (PR Newswire)
03:12PM	Loading…
Nov-02-23 03:12PM	3 Tech Stocks That Wall Street Loves More Than Nvidia (InvestorPlace)
Oct-31-23 09:00AM	BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures (PR Newswire) +12.78%
Oct-30-23 11:38AM	3 Top Penny Stocks to Make You a Millionaire in 5 Years (InvestorPlace)
Oct-12-23 07:00AM	BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment (PR Newswire)
Sep-28-23 07:00AM	BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC) (PR Newswire)
Sep-19-23 07:00AM	BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer (PR Newswire) +11.44%
Sep-14-23 05:36AM	BLRX: Go! (Zacks) +6.02%
Sep-11-23 07:00AM	BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma (PR Newswire)
Sep-05-23 06:04AM	BLRX: On Your Marks, Get Set (Zacks) +21.29%
Aug-31-23 08:18AM	BioLineRx Ltd. (NASDAQ:BLRX) Q2 2023 Earnings Call Transcript (Insider Monkey) +25.90%
Aug-30-23 07:00AM	BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Aug-22-23 07:00AM	BioLineRx to Report Second Quarter 2023 Results on August 30, 2023 (PR Newswire)
Aug-07-23 02:34PM	3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now (InvestorPlace)
Jul-18-23 03:22PM	3 Smart Penny Stocks with Huge Potential (InvestorPlace)
Jul-17-23 07:00AM	BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide (PR Newswire)
02:00PM	Loading…
Jun-29-23 02:00PM	The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023 (InvestorPlace)
Jun-07-23 05:25AM	BLRX: First Quarter Results (Zacks Small Cap Research)
May-24-23 07:00AM	BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
May-17-23 07:00AM	BioLineRx to Report First Quarter 2023 Results on May 24, 2023 (PR Newswire) +11.11%
May-04-23 01:56PM	7 High-Potential Penny Stocks in the Biotech Sector (InvestorPlace)
Apr-25-23 07:00AM	BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Apr-17-23 11:00AM	BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma (PR Newswire)
Apr-04-23 08:21PM	The 3 Best Biotech Stocks Under $1 to Buy for April (InvestorPlace)
Mar-24-23 07:15AM	BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 11:42AM	BLRX: Confidence in a Strong Launch (Zacks Small Cap Research)
Mar-22-23 07:00AM	BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Mar-15-23 07:00AM	BioLineRx to Report 2022 Annual Financial Results on March 22, 2023 (PR Newswire)
Mar-06-23 07:00AM	BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease (PR Newswire)
Jan-04-23 07:00AM	BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer (PR Newswire) +6.72%
Dec-20-22 12:36PM	BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate (Benzinga)
07:00AM	BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors (PR Newswire)
Dec-05-22 04:00AM	BLRX: Self-Commercialization in the US (Zacks Small Cap Research)
Nov-28-22 04:30PM	BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event (PR Newswire)
Nov-15-22 07:00AM	BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Nov-10-22 04:30PM	BioLineRx to Report Third Quarter 2022 Results on November 15, 2022 (PR Newswire) -24.00%
07:00AM	BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization (PR Newswire)
Nov-04-22 04:30PM	BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Nov-03-22 09:11AM	BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Nov-02-22 09:21AM	BLRX: Cast Off the Bowlines: Aphexda Commercialization (Zacks Small Cap Research)
Sep-27-22 07:00AM	BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization (PR Newswire)
Sep-19-22 08:00AM	BioLineRx Announces $15 Million Registered Direct Offering (PR Newswire) -33.77%
Sep-15-22 12:38PM	BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer (Benzinga)
07:00AM	BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital (PR Newswire)
Sep-12-22 07:00AM	BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization (PR Newswire) -9.89%
Aug-18-22 07:47AM	BLRX: September NDA (Zacks Small Cap Research)
Aug-16-22 07:00AM	BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) -6.28%
Aug-11-22 07:00AM	BioLineRx to Report Second Quarter 2022 Results on August 16, 2022 (PR Newswire)
Jun-29-22 08:00AM	BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures (PR Newswire) -5.38%
Jun-28-22 07:00AM	BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC) (PR Newswire)
Jun-16-22 07:00AM	BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer (PR Newswire)
May-12-22 10:16AM	BLRX: First Quarter 2022 Operational and Financial Results (Zacks Small Cap Research)
May-11-22 07:00AM	BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) -12.40%
May-05-22 07:00AM	BioLineRx to Report First Quarter 2022 Results on May 11, 2022 (PR Newswire)
Mar-17-22 08:55AM	BLRX: 2021 Results (Zacks Small Cap Research)
Mar-16-22 07:00AM	BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update (PR Newswire)
Mar-10-22 07:00AM	BioLineRx to Report 2021 Annual Results on March 16, 2022 (PR Newswire)
Mar-03-22 07:00AM	BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization (PR Newswire)
Jan-31-22 04:20AM	BLRX: Initiating on BioLineRx: Mobilizing the Troops with Motixafortide (Zacks Small Cap Research) +5.20%
Jan-24-22 07:00AM	BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors (PR Newswire)
Jan-18-22 07:00AM	BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients (PR Newswire) +8.46%
Dec-17-21 07:00AM	BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (PR Newswire) +5.96%
Dec-15-21 07:00AM	BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB) (PR Newswire)
Nov-18-21 07:00AM	BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
Nov-12-21 07:16AM	BioLineRx to Report Third Quarter 2021 Results on November 18, 2021 (PR Newswire)
Nov-04-21 09:15AM	BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (PR Newswire)
Oct-13-21 08:30AM	BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization (PR Newswire) +8.75%
Oct-06-21 04:38AM	11 Best Stocks for Long Term Growth (Insider Monkey)
Aug-18-21 07:00AM	BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
Aug-12-21 09:30AM	BioLineRx to Report Second Quarter 2021 Results on August 18, 2021 (PR Newswire)
Jun-30-21 08:58AM	Is Bioline RX Ltd (BLRX) A Good Stock To Buy? (Insider Monkey)
Jun-04-21 09:04AM	New Strong Sell Stocks for June 4th (Zacks)
May-26-21 07:00AM	BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
May-20-21 07:00AM	BioLineRx to Report First Quarter 2021 Results on May 26, 2021 (PR Newswire) +6.71%
May-04-21 08:56AM	BioLine RX rockets on heavy volume after 'strikingly positive' trial data on cancer treatment (MarketWatch) +52.98%
08:19AM	BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma Patients (Benzinga)
07:00AM	BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients (PR Newswire)
Apr-15-21 07:14AM	BioLineRx Announces Presentation at 2021 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Feb-23-21 07:45AM	BioLineRx Ltd. to Host Earnings Call (ACCESSWIRE)
07:00AM	BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update (PR Newswire)
Feb-17-21 07:00AM	BioLineRx to Report Annual 2020 Results on February 23, 2021 (PR Newswire) +7.53%
Jan-28-21 11:31AM	These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts (TipRanks) +23.11%
Jan-22-21 04:15PM	BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter (PR Newswire)
Jan-19-21 09:42PM	BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million (PR Newswire) +14.03%
04:55PM	BioLineRx Announces $10 Million Bought Deal Offering (PR Newswire)
Jan-07-21 09:28AM	RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation (Zacks)

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLRX

Bioline Rx Ltd ADR

Upgrade your FINVIZ experience